Pelthos Therapeutics Inc. Appoints Andrew J. Einhorn to Board of Directors

Pelthos Therapeutics Inc. announced the appointment of Andrew J. Einhorn to its Board of Directors, effective December 23, 2025. The Board was expanded from seven to eight members to accommodate this appointment. Mr. Einhorn, aged 66, brings extensive experience in finance, capital markets, and the life sciences sector. He currently serves as a fractional Chief Financial Officer and Strategic Advisor at Danforth Advisors, LLC, and has held previous executive finance roles at various biotechnology and pharmaceutical companies, including RVL Pharmaceuticals plc, Edge Therapeutics, and Oceana Therapeutics. He also has experience in investment banking and public accounting. Mr. Einhorn has been deemed an independent director and will serve on the Audit Committee and the Compensation Committee of the Board until the 2026 annual meeting of shareholders. He will receive a grant of 12,000 restricted stock units (RSUs) under the Company's 2023 Equity Incentive Plan, which will vest on January 1, 2027. An indemnification agreement has been entered into with Mr. Einhorn, consistent with those provided to other directors and officers.